REPLIGEN CORP Convertible Debt, Noncurrent
REPLIGEN CORP (RGEN) had Convertible Debt, Noncurrent of $533.73 million as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:ConvertibleDebtNoncurrent · last filed 2025-08-07
- 2025-06-30: Convertible Debt, Noncurrent $533.73M.
- 2025-03-31: Convertible Debt, Noncurrent $529.61M.
- 2024-12-31: Convertible Debt, Noncurrent $525.57M.
- 2024-09-30: Convertible Debt, Noncurrent $521.61M.
| Period end | Convertible Debt, Noncurrent |
|---|---|
| 2025-06-30 | $533.73M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $529.61M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $525.57M 10-Q · filed 2025-08-07 |
| 2024-09-30 | $521.61M 10-Q · filed 2024-11-18 |
| 2024-06-30 | $517.73M 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $513.92M 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $510.14M 10-K · filed 2025-03-14 |
| 2022-12-31 | $0.00 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |